BECLOMETHASONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H29ClO5
Molecular Weight	408.916
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=NBMKJKDGKREAPL-DVTGEIKXSA-N

InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H29ClO5
Molecular Weight	408.916
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020911s025lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/qvar-beclomethasone-inhaled-343427

Beclometasone dipropionate or beclomethasone dipropionate is sold under the brand name Qvar among others. Beclomethasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Beclomethasone dipropionate is a prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP). Beclomethasone 17 monopropionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor, which is approximately 13 times that of dexamethasone, 6 times that of triamcinolone acetonide, 1.5 times that of budesonide and 25 times that of beclomethasone dipropionate. The clinical significance of these findings is unknown. Studies in patients with asthma have shown a favorable ratio between topical anti-inflammatory activity and systemic corticosteroid effects with recommended doses of QVAR. Beclometasone dipropionate was first patented in 1962 and used medically in 1972. Common side effects with the inhaled form include respiratory infections, headaches, and throat inflammation. Serious side effects include an increased risk of infection, cataracts, Cushing’s syndrome, and severe allergic reactions. Long term use of the pill form may cause adrenal insufficiency. The pills may also cause mood or personality changes. The inhaled form is generally regarded as safe in pregnancy. Beclometasone is mainly a glucocorticoid.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16507850	Agonist 2662

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 237 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020911s025lbl.pdf	Palliative		Approved 8360	QVAR® 40 Approved Use QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Launch Date 9.6897597E11

C_max

Value	Dose	Analyte	Population
3103.4 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6635.1 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
181.95 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
262.65 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
88 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
283.5 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
623.6 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
88.23 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1661.53 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
0.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.278 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.457 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
13% OTHER GOV https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Beconase_AQ/pdf/BECONASE-PI-PIL.PDF			BECLOMETHASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
320 ug single, respiratory Highest studied dose Dose: 320 ug Route: respiratory Route: single Dose: 320 ug Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/	healthy, 18 - 45 years n = 66 Health Status: healthy Age Group: 18 - 45 years Sex: M Population Size: 66 Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/	Disc. AE: Presyncope... Other AEs: Headache, Nausea... AEs leading to discontinuation/dose reduction: Presyncope (1 patient) Other AEs: Headache (2 patients) Nausea (1 patient) Tonsillar hypertrophy (1 patient) Cerumen impaction (1 patient) Oropharyngeal pain (1 patient) Anxiety (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/
40 ug 2 times / day steady, respiratory Recommended Dose: 40 ug, 2 times / day Route: respiratory Route: steady Dose: 40 ug, 2 times / day Co-administed with:: albuterol(360 ug) Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	unhealthy, 5-18 years n = 71 Health Status: unhealthy Condition: asthma Age Group: 5-18 years Sex: M+F Population Size: 71 Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/
40 ug 2 times / day steady, respiratory Recommended Dose: 40 ug, 2 times / day Route: respiratory Route: steady Dose: 40 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	unhealthy, 5-18 years n = 72 Health Status: unhealthy Condition: asthma Age Group: 5-18 years Sex: M+F Population Size: 72 Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/
320 ug 2 times / day steady, respiratory Highest studied dose Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	unhealthy, adult n = 56 Health Status: unhealthy Condition: asthma Age Group: adult Sex: unknown Population Size: 56 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	Other AEs: Headache, Pain... Other AEs: Headache (25%) Pain (5%) Back pain (4%) Dysphonia (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf
320 ug 1 times / day steady, respiratory Dose: 320 ug, 1 times / day Route: respiratory Route: steady Dose: 320 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/	unhealthy, adults and children n = 219 Health Status: unhealthy Condition: allergic rhinitis Age Group: adults and children Sex: unknown Population Size: 219 Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/	Disc. AE: Nasal mucosal disorder NOS... AEs leading to discontinuation/dose reduction: Nasal mucosal disorder NOS (17 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/
80 ug 1 times / day steady, respiratory Dose: 80 ug, 1 times / day Route: respiratory Route: steady Dose: 80 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01697956	unhealthy, child n = 67 Health Status: unhealthy Condition: Perennial Allergic Rhinitis Age Group: child Population Size: 67 Sources: https://clinicaltrials.gov/ct2/show/NCT01697956	Other AEs: Epistaxis, Pyrexia... Other AEs: Epistaxis (below serious, 5 patients) Pyrexia (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01697956
80 ug 1 times / day steady, respiratory Dose: 80 ug, 1 times / day Route: respiratory Route: steady Dose: 80 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01783548	unhealthy, child n = 362 Health Status: unhealthy Condition: Perennial Allergic Rhinitis Age Group: child Population Size: 362 Sources: https://clinicaltrials.gov/ct2/show/NCT01783548	Other AEs: Epistaxis... Other AEs: Epistaxis (below serious, 18 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01783548

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inducer 768	inducer 383

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 691 OATP1B1 781 OATP1B3 700	CYP3A5 391 CYP3A7 110 esterase 70 P-gp 1527	UGT2B10 2 UGT2B17 2 CYP1A2 689 UGT1A 2 P-gp 257 MRP1 48 MRP2 111

Drug as perpetrator

Target	Modality	Activity
OATP1B3 709	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864424/	yes [IC50 1.4 uM]
OATP1B1 796	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864424/	yes [IC50 6.7 uM]
BCRP 765	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/15365089/	yes [Inhibition 40.4 uM]
CYP1A2 1673	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
CYP2C9 1803	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
CYP3A4 1909	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
MRP1 172	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
MRP2 459	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
P-gp 1626	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT1A 5	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT2B10 27	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT2B17 20	inducer 1542 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes

Drug as victim

Target	Modality	Activity
CYP3A7 110	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	no
CYP3A4 1709	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes
CYP3A5 391	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/22464980/ Page: 6.0	yes
esterase 70	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3001	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3001
ChemicalBook	CB7694093	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7694093
MolPort	MolPort-003-844-701	https://www.molport.com/shop/molecule-link/MolPort-003-844-701
ZINC	ZINC000004097285	http://zinc15.docking.org/substances/ZINC000004097285
eMolecules	31224812	https://www.emolecules.com/cgi-bin/more?vid=31224812

PubMed

Title	Date	PubMed
Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy.	2001	11759189
Small airway inflammation in asthma.	2001	11737932
Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control.	2001	11694816
Oral steroids for bronchiectasis (stable and acute exacerbations).	2001	11687146
[A case of sarcoidosis exacerbated during improvement of bronchial asthma].	2001 Apr	11398336
[Effect of fluticasone propionate at half dose of beclomethasone dipropionate divided twice daily and once daily in asthmatics inhaling beclomethasone dipropionate 800 micrograms daily or more].	2001 Apr	11398334
[Therapy participation in ambulatory asthma patients: empirical comparison of compliance rates using different operationalization methods for drug compliance].	2001 Apr	11393046
[Recent advance in pulmonary function tests--advance in pulmonary function tests for diagnosis and management of asthma].	2001 Apr	11391945
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.	2001 Aug	11529281
Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma.	2001 Aug	11527250
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.	2001 Aug	11509329
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).	2001 Aug	11483846
Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction.	2001 Aug 1	11500334
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.	2001 Aug 4	11485952
Electro-hydrodynamic atomization of drug solutions for inhalation purposes.	2001 Dec	11717241
[Tracheobronchopathia osteochondroplastica].	2001 Jul	11802998
Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.	2001 Jul	11453895
A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism.	2001 Jul	11447392
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).	2001 Jul-Aug	11674923
Treatment update: nonallergic rhinitis.	2001 Jul-Aug	11552668
A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.	2001 Jun	11559968
[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].	2001 Jun	11530386
The efficacy and safety of asthma medications during pregnancy.	2001 Jun	11453610
Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.	2001 Jun 8	11549975
[Stabilization of two patients with brittle asthma by inhaled beclomethasone dipropionate with small particle size].	2001 May	11449610
A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma.	2001 May	11392363
Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma.	2001 Nov	11730186
Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients : a 4-year longitudinal study.	2001 Nov	11713121
Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate.	2001 Nov	11699053
Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial.	2001 Nov	11695935
Apoptosis of airway epithelial cells induced by corticosteroids.	2001 Nov 15	11734450
Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis.	2001 Nov 23	11730731
[Inhaled corticosteroid therapy in childhood asthma].	2001 Oct	11676147
[Recent advance in inhaled corticosteroid therapy].	2001 Oct	11676146
[Inhaled corticosteroids: first-line therapy in asthma].	2001 Oct	11676140
What's new: newly approved drugs for children.	2001 Oct	11581490
Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study.	2001 Oct	11568990
Symptomatic adrenal insufficiency during inhaled corticosteroid treatment.	2001 Oct	11567945
Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma.	2001 Oct 20	11668133
Chronic asthma.	2001 Oct 27	11679388
Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate.	2001 Sep	11555383
Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis.	2001 Sep	11551252
Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone.	2001 Sep 15	11587988
Long-acting inhaled beta(2)-agonist therapy in asthma.	2001 Sep 15	11587972
Aerosol characterization of nebulized intranasal glucocorticoid formulations.	2001 Summer	11681655
Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer.	2001 Summer	11681653
Growth factors in idiopathic pulmonary fibrosis: relative roles.	2002	11806848
Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle.	2002	11806846
Inhaled steroids for children's acute asthma exacerbations?	2002 Jan	11814283
On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.	2002 Jan 30	11782057

Patents

Sample Use Guides

In Vivo Use Guide

Administer QVAR (beclomethasone dipropionate HFA 40 ug) by the orally inhaled route only. Patients should prime QVAR by actuating into the air twice before using for the first time or if QVAR has not been used for over 10 days.

Route of Administration: Other

In Vitro Use Guide

Incubation of challenged rings (bronchial rings from nonatopic humans) for 3 h with 3 x 10(-6) M beclomethasone dipropionate (BDP) restored the relaxant effect, suggesting reversal of beta(2)-AR pathway dysfunction.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:11:30 UTC 2023` Edited by `admin` on `Thu Jul 06 22:11:30 UTC 2023`
Record UNII	KGZ1SLC28Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BECLOMETHASONE

Common Name

English

BECLOMETASONE PROPIONATE

Common Name

English

beclometasone [INN]

Common Name

English

BECLOMETHASONE [VANDF]

Common Name

English

BECLOMETHASONE [MI]

Common Name

English

BECLOMETASONE

Official Name

English

9-CHLORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE

Systematic Name

English

BECLOMETASON

Brand Name

English

Beclometasone [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521